First Manhattan’s BridgeBio Pharma BBIO Stock Holding History

First Manhattan’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-27,490	Closed	-$473K	–	1495
2023 Q2	$473K	Hold	27,490	–	–	﹤0.01%	495
2023 Q1	$456K	Hold	27,490	–	–	﹤0.01%	524
2022 Q4	$209K	Hold	27,490	–	–	﹤0.01%	690
2022 Q3	$273K	Sell	27,490 -60,000	-69%	-$623K	﹤0.01%	632
2022 Q2	$794K	Buy	+87,490	New	+$732K	﹤0.01%	456
2021 Q4	–	Sell	-400	Closed	-$18K	–	1570
2021 Q3	$18K	Hold	400	–	–	﹤0.01%	1178
2021 Q2	$24K	Hold	400	–	–	﹤0.01%	1125
2021 Q1	$24K	Buy	+400	New	+$26.2K	﹤0.01%	1102

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

First Manhattan's BBIO Position: Q3 2023 in Review

First Manhattan sold out of BridgeBio Pharma (BBIO) in Q3 2023, closing a stake of 27,490 shares — an estimated $473K sold.

First Manhattan first reported a position in BBIO in Q1 2021 and held it in 8 quarters. The position peaked at $794K in Q2 2022. 221 funds tracked by Wall St. Rank hold BBIO as of Q3 2023.

First Manhattan reported no remaining BridgeBio Pharma position as of Q3 2023 after selling out during the quarter.
First Manhattan sold 27,490 BridgeBio Pharma shares in Q3 2023, an estimated $473K.
First Manhattan first reported a position in BridgeBio Pharma in Q1 2021 and held it in 8 quarters.
First Manhattan's BridgeBio Pharma position peaked at $794K in Q2 2022.
221 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2023.

Based on First Manhattan's 13F filing for Q3 2023, filed 14 Nov 2023.